ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
2seventy bio Inc

2seventy bio Inc (TSVT)

3.12
0.01
( 0.32% )
Actualizado: 14:06:41

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
3.12
Postura de Compra
3.11
Postura de Venta
3.13
Volume Operado de la Acción
147,427
3.02 Rango del Día 3.16
1.535 Rango de 52 semanas 6.40
Capitalización de Mercado [m]
Precio Anterior
3.11
Precio de Apertura
3.11
Última hora de negociación
14:08:33
Volumen financiero
US$ 456,500
Precio Promedio Ponderado
3.0965
Volumen promedio (3 m)
313,325
Acciones en circulación
51,588,420
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.74
Beneficio por acción (BPA)
-4.22
turnover
100.39M
Beneficio neto
-217.57M

Acerca de 2seventy bio Inc

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
2seventy bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TSVT. The last closing price for 2seventy bio was US$3.11. Over the last year, 2seventy bio shares have traded in a share price range of US$ 1.535 to US$ 6.40.

2seventy bio currently has 51,588,420 shares in issue. The market capitalisation of 2seventy bio is US$160.44 million. 2seventy bio has a price to earnings ratio (PE ratio) of -0.74.

TSVT Últimas noticias

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in...

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants...

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and...

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-1.01-24.45520581114.134.31953.023694723.41269901CS
4-1.94-38.33992094865.065.123.023386944.37603542CS
12-1.38-30.66666666674.55.33.023133254.63033861CS
26-1.23-28.2758620694.355.33.023957084.40009089CS
521.3778.28571428571.756.41.5359045504.19588525CS
156-33.02-91.366906474836.1436.151.5358094867.96313272CS
260-23.01-88.059701492526.1344.341.5358063318.26911408CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CRNCCerence Inc
US$ 6.099
(116.28%)
71.27M
WORXSCWorx Corporation
US$ 2.05
(109.18%)
131.71M
ARQQArqit Quantum Inc
US$ 10.7901
(47.00%)
743.81k
SPAISafe Pro Group Inc
US$ 4.61
(44.06%)
39.82M
PROCProcaps Group SA
US$ 0.771
(34.91%)
1.2M
SKKSKK Holdings Limited
US$ 0.8365
(-81.66%)
28M
TMTCTMT Acquisition Corporation
US$ 2.43
(-62.27%)
360.04k
WCTWellchange Holdings Company Limited
US$ 1.2657
(-61.88%)
1.95M
TMTCUTMT Acquisition Corporation
US$ 2.99
(-55.24%)
11.76k
GLXGGalaxy Payroll Group Ltd
US$ 1.81
(-53.71%)
2.23M
CDTConduit Pharmaceuticals Inc
US$ 0.1078
(16.79%)
554.41M
NVDANVIDIA Corporation
US$ 147.62
(1.19%)
324.48M
ELABElevai Labs Inc
US$ 0.0202
(-5.61%)
220.57M
AKTSAkoustis Technologies Inc
US$ 0.102
(17.11%)
200.32M
MARAMARA Holdings Inc
US$ 24.374
(7.71%)
139.59M

TSVT Discussion

Ver más
Monksdream Monksdream 3 meses hace
TSVT under $5
👍️0
Monksdream Monksdream 7 meses hace
TSVT under $5
👍️0
Invest-in-America Invest-in-America 8 meses hace
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 9 meses hace
TSVT 10Q due March 5
👍️0
molee molee 10 meses hace
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 11 meses hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 año hace
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 año hace
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

Su Consulta Reciente

Delayed Upgrade Clock